Table II.
Association between miR-93 expression and the clinical characteristics of patients with AML.
| Clinical data | miR-93 expression in AML tissues
|
χ2/F-value | P-value | |
|---|---|---|---|---|
| Low expression (n=14) | High expression (n=14) | |||
| Sex | ||||
| Male | 9 (64.29%) | 7 (50.00%) | 0.583 | 0.445 |
| Female | 5 (35.71%) | 7 (50.00%) | ||
| Age, years; median (range) | 45.5 (19-63) | 45.0 (34-71) | 1.341 | 0.897 |
| FAB classification | ||||
| M0 | 1 (7.14%) | 2 (14.29%) | 5.082 | 0.406 |
| M1 | 8 (57.14%) | 3 (21.43%) | ||
| M2 | 3 (21.43%) | 4 (28.57%) | ||
| M3 | 0 (0.00%) | 2 (14.29%) | ||
| M4 | 1 (7.14%) | 2 (14.29%) | ||
| M5 | 1 (7.14%) | 1 (7.14%) | ||
| M6 | 0 (0.00%) | 0 (0.00%) | - | - |
| WBC (×109/l); median (range) | 48.13 (30.98-122.85) | 85.69 (21.59-166.16) | 1.272 | <0.001 |
AML, acute myeloid leukemia; miR-93, microRNA-93; FAB, French-American-British; WBC, white blood cells. Sex and FAB classification were examined using a Chi-squared test; Age and WBC were examined using a t-test.